Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCL Carnival	$28.67 -1.5%	$24.18	$13.78 ▼ $30.46	$33.47B	2.61	25.26 million shs	14.57 million shs
HES Hess	$153.28 +0.8%	$137.31	$123.79 ▼ $161.69	$47.41B	0.62	1.85 million shs	2.78 million shs
KRA Kraton	$46.49	$46.37	$30.48 ▼ $46.74	$1.50B	2.08	379,776 shs	N/A
MGM MGM Resorts International	$37.94 -2.3%	$33.61	$25.30 ▼ $47.26	$10.33B	1.76	4.95 million shs	4.34 million shs
MRNA Moderna	$33.64 -1.9%	$27.09	$23.15 ▼ $129.39	$13.01B	1.84	8.84 million shs	6.92 million shs
PFE Pfizer	$25.65 -0.5%	$23.86	$20.92 ▼ $31.54	$145.83B	0.58	41.82 million shs	34.84 million shs
XLRN Acceleron Pharma	$178.75	$176.25	$108.82 ▼ $189.99	$10.93B	0.13	572,759 shs	N/A

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCL Carnival	+1.07%	-2.84%	+18.76%	+64.50%	+64.09%
HES Hess	+0.73%	+6.82%	+9.70%	+18.46%	+3.01%
KRA Kraton	0.00%	0.00%	0.00%	0.00%	0.00%
MGM MGM Resorts International	+3.10%	+3.77%	+16.27%	+32.20%	-11.51%
MRNA Moderna	+4.54%	+12.50%	+23.84%	+30.84%	-70.81%
PFE Pfizer	+0.81%	+1.27%	+6.06%	+17.72%	-9.11%
XLRN Acceleron Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CCL Carnival	4.6235 of 5 stars	2.3	2.0	0.0	3.1	3.2	1.7	4.4
HES Hess	4.7122 of 5 stars	2.3	5.0	2.5	1.2	2.3	2.5	3.1
KRA Kraton	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGM MGM Resorts International	4.7662 of 5 stars	4.3	1.0	0.0	1.8	2.7	2.5	3.1
MRNA Moderna	4.3129 of 5 stars	4.0	1.0	0.0	4.6	2.1	2.5	0.6
PFE Pfizer	4.9685 of 5 stars	3.2	3.0	4.2	4.5	2.6	1.7	3.1
XLRN Acceleron Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CCL Carnival	2.65	Moderate Buy	$28.65	-0.08% Downside
HES Hess	2.55	Moderate Buy	$163.70	6.80% Upside
KRA Kraton	0.00	N/A	N/A	N/A
MGM MGM Resorts International	2.65	Moderate Buy	$47.67	25.64% Upside
MRNA Moderna	2.04	Hold	$46.61	38.56% Upside
PFE Pfizer	2.45	Hold	$28.55	11.31% Upside
XLRN Acceleron Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MRNA, CCL, PFE, KRA, HES, XLRN, and MGM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	HES Hess	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$146.58 ➝ $155.00
7/11/2025	MGM MGM Resorts International	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$37.00 ➝ $38.00
7/11/2025	MGM MGM Resorts International	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$44.00 ➝ $48.00
7/9/2025	MGM MGM Resorts International	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy	$55.00 ➝ $57.00
7/8/2025	MGM MGM Resorts International	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$37.00 ➝ $42.00
7/7/2025	MGM MGM Resorts International	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$34.00
7/2/2025	HES Hess	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$147.00 ➝ $153.00
6/26/2025	MGM MGM Resorts International	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/26/2025	CCL Carnival	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $24.00
6/26/2025	HES Hess	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$193.00 ➝ $184.00
6/26/2025	MGM MGM Resorts International	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CCL Carnival	$25.02B	1.34	$3.95 per share	7.25	$8.57 per share	3.35
HES Hess	$13.02B	3.64	$18.03 per share	8.50	$38.96 per share	3.93
KRA Kraton	$1.97B	0.76	$9.37 per share	4.96	$26.38 per share	1.76
MGM MGM Resorts International	$17.24B	0.60	$5.63 per share	6.74	$12.38 per share	3.06
MRNA Moderna	$3.24B	4.02	N/A	N/A	$28.33 per share	1.19
PFE Pfizer	$62.46B	2.33	$4.38 per share	5.86	$15.62 per share	1.64
XLRN Acceleron Pharma	$92.52M	118.15	N/A	N/A	$11.74 per share	15.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CCL Carnival	$1.92B	$1.85	15.50	13.72	0.64	9.72%	27.88%	5.20%	9/29/2025 (Estimated)
HES Hess	$2.77B	$7.23	21.20	13.33	N/A	17.65%	21.78%	9.72%	7/30/2025 (Estimated)
KRA Kraton	$170.23M	$3.06	15.19	14.67	N/A	8.64%	14.17%	4.18%	N/A
MGM MGM Resorts International	$746.56M	$2.24	16.94	13.22	2.60	3.95%	20.64%	1.82%	7/30/2025 (Estimated)
MRNA Moderna	-$3.56B	-$8.73	N/A	N/A	N/A	-105.67%	-28.69%	-21.94%	7/30/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	18.59	8.47	0.93	12.62%	20.33%	8.53%	8/5/2025 (Estimated)
XLRN Acceleron Pharma	-$166.03M	-$4.21	N/A	N/A	N/A	-226.01%	-32.11%	-29.45%	N/A

Latest MRNA, CCL, PFE, KRA, HES, XLRN, and MGM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	MRNA Moderna	-$2.97	N/A	N/A	N/A	$116.26 million	N/A
8/5/2025	Q2 2025	PFE Pfizer	$0.57	N/A	N/A	N/A	$13.43 billion	N/A
7/30/2025	Q2 2025	HES Hess	$1.22	N/A	N/A	N/A	$2.69 billion	N/A
7/30/2025	Q2 2025	MGM MGM Resorts International	$0.55	N/A	N/A	N/A	$4.28 billion	N/A
6/24/2025	Q2 2025	CCL Carnival	$0.24	$0.35	+$0.11	$0.42	$6.20 billion	$6.33 billion
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million
4/30/2025	Q1 2025	HES Hess	$1.95	$1.81	-$0.14	$1.39	$2.95 billion	$2.92 billion
4/30/2025	Q1 2025	MGM MGM Resorts International	$0.50	$0.69	+$0.19	$0.51	$4.29 billion	$4.28 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CCL Carnival	N/A	N/A	N/A	N/A	N/A
HES Hess	$2.00	1.30%	N/A	27.66%	3 Years
KRA Kraton	N/A	N/A	N/A	N/A	N/A
MGM MGM Resorts International	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.71%	N/A	124.64%	16 Years
XLRN Acceleron Pharma	N/A	N/A	N/A	N/A	N/A

Latest MRNA, CCL, PFE, KRA, HES, XLRN, and MGM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
5/14/2025	HES Hess	quarterly	$0.50	1.49%	6/16/2025	6/16/2025	6/30/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CCL Carnival	2.58	0.34	0.30
HES Hess	0.71	1.08	0.91
KRA Kraton	0.97	1.64	0.75
MGM MGM Resorts International	1.79	1.31	1.26
MRNA Moderna	N/A	4.22	4.14
PFE Pfizer	0.64	1.26	0.96
XLRN Acceleron Pharma	N/A	12.14	12.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CCL Carnival	67.19%
HES Hess	88.51%
KRA Kraton	99.81%
MGM MGM Resorts International	68.11%
MRNA Moderna	75.33%
PFE Pfizer	68.36%
XLRN Acceleron Pharma	90.35%

Insider Ownership

Company	Insider Ownership
CCL Carnival	7.60%
HES Hess	9.10%
KRA Kraton	3.11%
MGM MGM Resorts International	3.06%
MRNA Moderna	11.00%
PFE Pfizer	0.06%
XLRN Acceleron Pharma	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CCL Carnival	100,000	1.17 billion	1.08 billion	Optionable
HES Hess	1,797	309.31 million	281.16 million	Optionable
KRA Kraton	1,751	32.23 million	31.23 million	Optionable
MGM MGM Resorts International	63,000	272.15 million	263.82 million	Optionable
MRNA Moderna	5,800	386.74 million	344.20 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
XLRN Acceleron Pharma	312	61.16 million	60.12 million	Optionable

MRNA, CCL, PFE, KRA, HES, XLRN, and MGM Headlines

Recent News About These Companies

Acceleron P Stock Price Today | NASDAQ: XLRN Live - Investing.com

June 28, 2025 | investing.com

UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal

January 2, 2025 | benzinga.com

Acceleron advances cold fusion technology

December 17, 2024 | neimagazine.comN

Acceleron Banks on Muons for Colder Fusion

December 6, 2024 | msn.com

Merck preps filings after blockbuster-in-waiting Winrevair succeeds in severe PAH study

November 26, 2024 | fiercepharma.comF

Acceleron attracts turbocharged demand for debut Swissie

October 17, 2024 | globalcapital.comG

Acceleron Fusion has raised $15M to take a stab at colder fusion, filing reveals

October 5, 2024 | techcrunch.comT

Acceleron Fusion has raised $15M to take another stab at cold fusion, filing reveals

October 1, 2024 | yahoo.com

Merck confirms $11.5bn Acceleron takeover deal

August 6, 2024 | pharmaphorum.comP

Earnings to Watch Next Week: ON Semiconductor, Ferrari, General Motors and Moderna in Focus

April 26, 2024 | fxempire.comF

Big Pharma Q1 earnings roundup: AstraZeneca, BMS, Merck, Sanofi

April 26, 2024 | mmm-online.comM

ORBIMED CAPITAL GP II LLC's Net Worth

February 27, 2024 | benzinga.com

XLRN Historical Data

October 20, 2023 | investing.com

MSD eyes March FDA decision on PAH drug sotatercept

October 15, 2023 | pharmaphorum.comP

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

April 15, 2023 | thestreet.com

Astellas Pharma Inc

March 17, 2023 | reuters.com

HempStreet partners with MGC Pharma launches ArtemiC

January 30, 2023 | health.economictimes.indiatimes.com

Acceleron Corp Becomes a Digital Correspondent Bank

December 14, 2022 | finance.yahoo.com

Pharma Contract Sales Market Report 2022-2032

November 30, 2022 | finance.yahoo.com

Merck to buy Imago for $1.35 bln to broaden portfolio of blood disorder drugs

November 21, 2022 | reuters.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Don’t Miss These 2 Small Quantum Stocks Poised to Pop
By Gabriel Osorio-Mazilli | June 24, 2025
View Don’t Miss These 2 Small Quantum Stocks Poised to Pop
2 Under the Radar Space & Defense Stocks With Huge Potential
By Leo Miller | July 1, 2025
View 2 Under the Radar Space & Defense Stocks With Huge Potential
Top 5 Stocks for July: Momentum-Driven Picks to Watch Now
By Thomas Hughes | June 30, 2025
View Top 5 Stocks for July: Momentum-Driven Picks to Watch Now
These 3 Dividend Stocks Combine Strong Yields With Upside
By Chris Markoch | June 20, 2025
View These 3 Dividend Stocks Combine Strong Yields With Upside
3 Stocks Set to Double—And There's Still Time to Buy
By Nathan Reiff | June 12, 2025
View 3 Stocks Set to Double—And There's Still Time to Buy

MRNA, CCL, PFE, KRA, HES, XLRN, and MGM Company Descriptions

Carnival NYSE:CCL

$28.67 -0.43 (-1.48%)

Closing price 03:59 PM Eastern

Extended Trading

$28.65 -0.02 (-0.07%)

As of 07:06 PM Eastern

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Hess NYSE:HES

$153.28 +1.24 (+0.81%)

Closing price 03:58 PM Eastern

Extended Trading

$153.48 +0.20 (+0.13%)

As of 05:58 PM Eastern

Hess Corporation, an exploration and production company, explores, develops, produces, purchases, transports, and sells crude oil, natural gas liquids (NGLs), and natural gas. The company operates in two segments, Exploration and Production, and Midstream. It conducts production operations primarily in the United States, Guyana, the Malaysia/Thailand Joint Development Area, and Malaysia; and exploration activities principally offshore Guyana, the U.S. Gulf of Mexico, and offshore Suriname and Canada. The company is also involved in gathering, compressing, and processing natural gas; fractionating NGLs; gathering, terminaling, loading, and transporting crude oil and NGL through rail car; and storing and terminaling propane, as well as providing water handling services primarily in the Bakken Shale plays in the Williston Basin area of North Dakota. The company was incorporated in 1920 and is headquartered in New York, New York.

Kraton NYSE:KRA

Kraton Corp. engages in the manufacture and marketing of styrenic block copolymers, specialty polymers, and other products primarily derived from pine wood pulping co-products. It operates through the Polymer and Chemical segment. The Polymer segment includes styrenic block copolymers and other engineered polymers business. The Chemical segment consists of pine-based specialty products business. The company was founded on February 28, 2001 and is headquartered in Houston, TX.

MGM Resorts International NYSE:MGM

$37.94 -0.90 (-2.32%)

Closing price 03:59 PM Eastern

Extended Trading

$37.89 -0.05 (-0.13%)

As of 06:58 PM Eastern

MGM Resorts International, through its subsidiaries, owns and operates casino, hotel, and entertainment resorts in the United States and internationally. The company operates through three segments: Las Vegas Strip Resorts, Regional Operations, and MGM China. Its casino resorts offer gaming, hotel, convention, dining, entertainment, retail, and other resort amenities. The company's casino operations include slots and table games, as well as online sports betting and iGaming through BetMGM. Its customers include premium gaming customers; leisure and wholesale travel customers; business travelers; and group customers, including conventions, trade associations, and small meetings. The company was formerly known as MGM MIRAGE and changed its name to MGM Resorts International in June 2010. MGM Resorts International was incorporated in 1986 and is based in Las Vegas, Nevada.

Moderna NASDAQ:MRNA

$33.64 -0.64 (-1.87%)

Closing price 04:00 PM Eastern

Extended Trading

$33.53 -0.11 (-0.31%)

As of 07:07 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer NYSE:PFE

$25.65 -0.13 (-0.50%)

Closing price 03:59 PM Eastern

Extended Trading

$25.62 -0.02 (-0.10%)

As of 07:07 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Acceleron Pharma NASDAQ:XLRN

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MRNA, CCL, PFE, KRA, HES, XLRN, and MGM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MRNA, CCL, PFE, KRA, HES, XLRN, and MGM Earnings

Compare Dividends

Latest MRNA, CCL, PFE, KRA, HES, XLRN, and MGM Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MRNA, CCL, PFE, KRA, HES, XLRN, and MGM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MRNA, CCL, PFE, KRA, HES, XLRN, and MGM Company Descriptions

Carnival NYSE:CCL

Hess NYSE:HES

Kraton NYSE:KRA

MGM Resorts International NYSE:MGM

Moderna NASDAQ:MRNA

Pfizer NYSE:PFE

Acceleron Pharma NASDAQ:XLRN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools